Brokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Target Price at $5.17

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has been given an average recommendation of “Moderate Buy” by the six analysts that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $5.17.

SGMO has been the topic of a number of analyst reports. Royal Bank of Canada reiterated a “sector perform” rating and issued a $2.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research report on Monday, April 7th. Finally, Truist Financial reduced their price target on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd.

Sangamo Therapeutics Stock Down 2.8%

Shares of SGMO stock opened at $0.70 on Monday. The firm has a market capitalization of $160.44 million, a P/E ratio of -0.93 and a beta of 1.46. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18. The stock’s fifty day simple moving average is $0.78 and its 200 day simple moving average is $1.36.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The firm had revenue of $7.55 million for the quarter, compared to the consensus estimate of $11.70 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. As a group, equities research analysts expect that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in SGMO. Point72 Asset Management L.P. acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at about $2,316,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at about $1,744,000. GSA Capital Partners LLP lifted its stake in shares of Sangamo Therapeutics by 2,962.2% in the 1st quarter. GSA Capital Partners LLP now owns 966,202 shares of the biopharmaceutical company’s stock valued at $634,000 after purchasing an additional 934,649 shares during the period. Acuta Capital Partners LLC acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at about $755,000. Finally, Two Sigma Advisers LP acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at about $722,000. 56.93% of the stock is owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.